Authorized purpose: Cartesion Prime PET/CT acquires cross-sectional CT images and PET radiopharmaceutical-distribution images and includes AiCE-i PET processing and a neural-network respiratory-gating workflow for supported examinations.
Clinical role
PET/CT acquisition, reconstruction, attenuation correction, fusion, visualization, and quantitative review.
Images and patients
PET/SPECT/Nuclear Medicine · Whole body, head, neck, cardiac, and other labeled PET/CT regions
Key limitation
Keep in mind: Radiopharmaceutical, scan range, patient-size, acquisition, reconstruction, attenuation-correction, dose, and quantitative limits are configuration-specific; decisions remain with qualified clinicians.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Cartesion Prime PET/CT acquires cross-sectional CT images and PET radiopharmaceutical-distribution images and includes AiCE-i PET processing and a neural-network respiratory-gating workflow for supported examinations.
Which images or clinical context are in scope?Modality: PET/SPECT/Nuclear Medicine Anatomy or clinical context: Whole body, head, neck, cardiac, and other labeled PET/CT regions Input: Positron-emission data, CT transmission data, patient and protocol information, and supported radiopharmaceutical studies.
Who uses it?Intended users: Qualified nuclear-medicine physicians, radiologists, technologists, and other trained PET/CT professionals.
What does the software produce?Output: Attenuation-corrected PET, CT, fused PET/CT, quantitative, and planning images for professional interpretation.
What is its most important limitation?Key limitation: Radiopharmaceutical, scan range, patient-size, acquisition, reconstruction, attenuation-correction, dose, and quantitative limits are configuration-specific; decisions remain with qualified clinicians.
Clinical takeaway. Clinical role: Cartesion Prime PET/CT acquires cross-sectional CT images and PET radiopharmaceutical-distribution images and includes AiCE-i PET processing and a neural-network respiratory-gating workflow for supported examinations.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports NEMA NU-2 phantom testing comparing AiCE2 with AiCE1, with results across all indices showing equivalence or improvement by AiCE2; a DRG2-versus-DRG1 evaluation on reconstructed clinical raw data from 11 total male and female patients that satisfied all prespecified criteria; and reviews by three physicians of ten (10) AiCE2 whole body cases and ten (10) respiratory-gated patients, with images judged of diagnostic quality. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Cartesion Prime PET/CT acquires cross-sectional CT images and PET radiopharmaceutical-distribution images and includes AiCE-i PET processing and a neural-network respiratory-gating workflow for supported examinations.
The exact FDA document reports NEMA NU-2 phantom testing comparing AiCE2 with AiCE1, with results across all indices showing equivalence or improvement by AiCE2; a DRG2-versus-DRG1 evaluation on reconstructed clinical raw data from 11 total male and female patients that satisfied all prespecified criteria; and reviews by three physicians of ten (10) AiCE2 whole body cases and ten (10) respiratory-gated patients, with images judged of diagnostic quality. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Phantom testing in accordance with NEMA NU-2, Section 7 was conducted in order to compare the Sharp, Standard and Smooth intensity settings available with AiCE2 to AiCE1," … "The results across all indices demonstrated either equivalence or improvement by AiCE2.". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports NEMA NU-2 phantom testing comparing AiCE2 with AiCE1, with results across all indices showing equivalence or improvement by AiCE2; a DRG2-versus-DRG1 evaluation on reconstructed clinical raw data from 11 total male and female patients that satisfied all prespecified criteria; and reviews by three physicians of ten (10) AiCE2 whole body cases and ten (10) respiratory-gated patients, with images judged of diagnostic quality. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "Phantom testing in accordance with NEMA NU-2, Section 7 was conducted in order to compare the Sharp, Standard and Smooth intensity settings available with AiCE2 to AiCE1," … "The results across all indices demonstrated either equivalence or improvement by AiCE2.". Read from the exact FDA decision document on 2026-11-14.
Sensitivity is not a product-wide endpoint for this system or software function. Compare only an exact endpoint, threshold, population, version, and source if one is later verified.
Reported specificity
Not applicable
Not applicable
Not applicable
Checked 2026-09-04
Specificity is not a product-wide endpoint for this system or software function. Compare only an exact endpoint, threshold, population, version, and source if one is later verified.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K251370 FDA evidence package for Cartesion Prime (PCD-1000A/3) V10.21
DesignFDA substantial-equivalence decision with PET, CT, reconstruction, respiratory-gating, image-quality, dose, and usability verification
PopulationWhole-body and labeled PET/CT examinations using supported radiopharmaceuticals, acquisition protocols, and qualified professionals
Scopeexact submission
Tested versionCartesion Prime PET/CT configuration described in K251370
IndependenceSponsor or vendor study
K251370
Manufacturer evidence submitted for the exact FDA decision. It is not independent clinical validation, and local technical, clinical, privacy, security, and workflow acceptance remains necessary.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K251370 by exact native submission identifier. This does not exclude product-family, later, or adverse-event information.
Public source
Exact FDA submission
Checked 2026-09-04
Exact-identifier review does not prove absence of all product-family safety signals.
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Positron-emission data, CT transmission data, patient and protocol information, and supported radiopharmaceutical studies.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The public exact-submission material does not establish a complete integration contract. Confirm DICOM, worklist, identity, interfaces, exports, routing, audit behavior, and downtime locally.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Field checked 2026-09-04 ·
AI processing
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The public exact-submission material does not establish the complete deployment topology, hosting responsibility, availability, upgrade path, or service contract.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-04 ·
Returned objects
Source context, not route validation: Attenuation-corrected PET, CT, fused PET/CT, quantitative, and planning images for professional interpretation.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Attenuation-corrected PET, CT, fused PET/CT, quantitative, and planning images for professional interpretation.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Canon Medical's cybersecurity page states that Canon imaging systems follow a software development life cycle governed by the NIST 800-53 Risk Management Framework adhering to Defense Health Agency certification requirements; FIPS 140-2 certified cipher standards; deny-all firewall configuration and near-real-time SIEM syslog export as premium offerings; a dedicated cybersecurity risk management team for threat intelligence monitoring, advisories and incident response; and published OS and third-party update policies. Vendor statement; no certification or test report was read.
Vendor-wide
Checked 2026-10-26
Vendor statement, not an attestation. Identity bridge: the page is on us.medical.canon, Canon Medical's own site (Canon Medical Systems USA), and describes Canon Medical imaging devices generally; the FDA applicant is Canon Medical Systems Corporation, named in the corporate name-change press release on the same domain. Regional page with general device claims; exact-release scope is not established.
Only qualified nuclear-medicine physicians, radiologists, technologists, and other trained pet/ct professionals should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
Exact public integration details remain incomplete; establish and test the supported input, output, identity, routing, archive, and downtime contract locally.
product family · checked 2026-09-04
Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally. Current vendor material is product-family context; confirm exact release, enabled options, deployment, and local compatibility.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Radiopharmaceutical, scan range, patient-size, acquisition, reconstruction, attenuation-correction, dose, and quantitative limits are configuration-specific; decisions remain with qualified clinicians.
exact submission · checked 2026-09-04
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-04
No exact-product price was found in the reviewed public material; productivity or value claims require local evidence.
Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Radiopharmaceutical, scan range, patient-size, acquisition, reconstruction, attenuation-correction, dose, and quantitative limits are configuration-specific; decisions remain with qualified clinicians.
product family · checked 2026-09-04
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. Current vendor material is product-family context; confirm exact release, enabled options, deployment, and local compatibility.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-20Last searched
27Fields reviewed
13Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, fda decision material, vendor product page, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Deployment: Not publicly available - checked 2026-09-04 - Exact FDA submission
The public exact-submission material does not establish the complete deployment topology, hosting responsibility, availability, upgrade path, or service contract.
Integration: Not publicly available - checked 2026-09-04 - Exact FDA submission
The public exact-submission material does not establish a complete integration contract. Confirm DICOM, worklist, identity, interfaces, exports, routing, audit behavior, and downtime locally.
Authorized purpose: uMI Panvivo variants acquire and display PET and CT information for anatomical and functional imaging, radiopharmaceutical distribution, attenuation correction, and the labeled body-region workflows.
Modality
PET/SPECT/Nuclear Medicine
Anatomy
Whole body; brain; head and neck; heart; lung; breast; gastrointestinal; urinary; genital; and musculoskeletal anatomy
Authorized purpose: uMI Panvivo PET/CT acquires anatomical CT and functional PET images of radiopharmaceutical distribution for qualified diagnostic and treatment-planning workflows, including labeled lung-cancer-screening use.
Modality
PET/SPECT/Nuclear Medicine
Anatomy
Whole body, head and neck, cardiac, and other labeled PET/CT regions
Authorized purpose: TruSPECT Processing Station receives, transfers, displays, stores, and processes radioisotope-tracer images for trained professionals; TruClear AI SPECT enhancement supports the existing image-processing workflow and does not replace clinical judgment.
Modality
PET/SPECT/Nuclear Medicine
Anatomy
Heart, organs, and body regions represented in SPECT studies
Authorized purpose: uMI Panvivo and Panvivo S acquire and display PET and CT information for anatomical and functional imaging, radiopharmaceutical distribution, and the labeled oncology, cardiology, neurology, infection, inflammation, radiotherapy-planning, and interventional workflows.
Modality
PET/SPECT/Nuclear Medicine
Anatomy
Whole body; brain; head and neck; heart; lung; breast; gastrointestinal; urinary; genital; and musculoskeletal anatomy
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.